Renal cell carcinoma treatment after first-line combinations

Porta C, Schmidinger M.
The Lancet, Vol 20, 10, P1332-1334, October 2019

Treatment of metastatic renal cell carcinoma has dramatically changed in the past two decades, moving from cytokine-based immunotherapy, to vascular endothelial growth factor (VEGF) pathway inhibitors, and to combinations of these inhibitors with novel immune checkpoint inhibitors. What was once defined as an “embarassment of riches” has now reached new, unexpected heights.

Read article
No Comments

Sorry, the comment form is closed at this time.

You don't have permission to register